Hyperphosphatemia: Its Consequences and Treatment in Patients With Chronic Renal Disease

https://doi.org/10.1016/S0272-6386(12)80446-XGet rights and content

Control of phosphorus accumulation in chronic renal insufficiency is crucial to the prevention of secondary hyperparathyroidism and metastatic calcification. In early renal failure, calcitriol levels are normal and parathyroid hormone levels are elevated. The phosphorus levels are maintained in the normal range by the phosphaturia induced by hyperparathyroidism. In this situation, dietary phosphorus restriction increases calcitriol levels and suppresses parathyroid hormone secretion. As renal failure progresses into late stages, hyperphosphatemia is evident along with low levels of calcitriol and worsening hyperparathyroidism. Phosphorus restriction will not affect calcitriol concentrations, yet parathyroid levels may decline. During long-term dialysis, urinary excretion of phosphorus is usually minimal. Therefore, phosphorus balance is determined primarily by the net amount absorbed by the bowel and the quantity removed during dialytic therapy. Given an adequate diet, no form of conventional dialysis is able to fully compensate for the gastrointestinal absorption of phosphorus. Hence, compounds that bind phosphorus in the bowel are often necessary. With the realization that the use of phosphorus binders containing aluminum leads to aluminum accumulation and its sequelae: osteomalacia, dementia, myopathy, and anemia, other phosphorus binders have been evaluated. Calcium carbonate has been investigated the most thoroughly and is in wide use. It is inexpensive and contains a high percent of elemental calcium. However, it is only modestly potent in the binding of phosphorus, and large doses are often necessary to attain satisfactory control of phosphorus. This may lead to hypercalcemia. One approach to this problem is to decrease the concentration of calcium in the dialysate. Alternatively, a more effective phosphorus binder may be used. Calcium acetate has been shown in acute studies to have twice the binding capacity of phosphorus per calcium absorbed than calcium carbonate. Whether use of this compound decreases the incidence of hypercalcemia is unproven. Calcium citrate increases the gastrointestinal absorption of aluminum and offers no advantage over calcium carbonate. Other compounds, such as calcium ketoacids and calcium alginate, have not been extensively studied and are not generally available. The use of phosphorus binders containing magnesium in conjunction with a dialysate low in magnesium may be efficacious. Large doses of magnesium will cause diarrhea and thus limit its use as a single agent. Reasons for failure to control hyperphosphatemia include poor compliance, improper prescription of binders, poor dissolution rates seen with some generic brands of calcium carbonate, and the presence of severe hyperparathyroidism. Optimal control of serum phosphorus in dialysis patients should always be viewed in the context of adequate nutrition and protein intake.

References (122)

  • LA Baxter et al.

    Stimulation of 25-hydroxyvitamin D31-alpha-hydroxylase by phosphate depletion

    J Biol Chem

    (1976)
  • E Slatopolsky et al.

    The role of phosphate restriction in the prevention of secondary hyperparathyroidism in chronic renal disease

    Kidney Int

    (1973)
  • AK Cheung et al.

    Determinations of serum 1,25(OH)2D levels in renal disease

    Kidney Int

    (1983)
  • JW Coburn et al.

    Study of intestinal absorption of calcium in patients with renal failure

    Kidney Int

    (1973)
  • G Maschio et al.

    Effects of dietary protein and phosphorus restriction on the progression of early renal failure

    Kidney Int

    (1982)
  • DW Windus et al.

    The short-term effects of a low protein diet in stable renal transplant recipients

    Am J Kidney Dis

    (1991)
  • JD Kopple et al.

    Effect of energy intake on nitrogen metabolism in nondialyzed patients in chronic renal failure

    Kidney Int

    (1986)
  • FA Gotch et al.

    A mechanistic analysis of the National Cooperative Dialysis Study (NCDS)

    Kidney Int

    (1985)
  • MJ Blumenkrantz et al.

    Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis

    Kidney Int

    (1982)
  • SH Hou et al.

    Calcium and phosphorus fluxes during hemodialsis with low calcium dialysate

    Am J Kidney Dis

    (1991)
  • VS Lim et al.

    Effect of hematocrit on solute removal during high efficiency hemodialysis

    Kidney Int

    (1990)
  • JA Delmez et al.

    Minerals, vitamin D and parathyroid hormone in continuous ambulatory peritoneal dialysis

    Kidney Int

    (1982)
  • IS Parkinson et al.

    Fracturing dialysis osteodystrophy and dialysis encephalopathy

    An epidemiological survey. Lancet

    (1979)
  • KC Norris et al.

    Clinical and laboratory features of aluminum-related bone disease

    Differences between sporadic and epidemic forms of the syndrome. Am J Kidney Dis

    (1985)
  • A Meyrier et al.

    The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis

    Kidney Int

    (1973)
  • IB Salusky et al.

    Oral calcium carbonate as a phosphate-binding agent in children on dialysis: Effect on plasma aluminum levels

    J Pediatr

    (1986)
  • E Slatopolsky et al.

    Long term effects of calcium carbonate and 2.5 mEq/L calcium dialysate on mineral metabolism

    Kidney Int

    (1989)
  • F Meric et al.

    Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy

    Am J Kidney Dis

    (1990)
  • ML Mai et al.

    Calcium acetate, an effective phosphorus binder in patients with renal failure

    Kidney Int

    (1989)
  • M Emmett et al.

    Calcium acetate control of serum phosphorus in hemodialysis patients

    Am J Kidney Dis

    (1991)
  • HM Cushner et al.

    Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF

    Kidney Int

    (1988)
  • JW Coburn et al.

    Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide

    Am J Kidney Dis

    (1991)
  • CR Nolan et al.

    Influence of calcium acetate or calcium citrate on intestinal aluminum absorption

    Kidney Int

    (1990)
  • DP Froment et al.

    Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate

    Kidney Int

    (1989)
  • E Bogin et al.

    Effect of parathyroid hormone on rat heart cells

    J Clin Invest

    (1981)
  • M Akmal et al.

    Role of parathyroid hormone in the glucose intolerance of chronic renal failure

    J Clin Invest

    (1985)
  • D Meytes et al.

    Effect of parathyroid hormone on erythropoiesis

    J Clin Invest

    (1981)
  • E Bogin et al.

    Effect of parathyroid hormone on osmotic fragility of human erythrocytes

    J Clin Invest

    (1982)
  • KK Arora et al.

    Calcific cardiomyopathy in advanced renal failure

    Arch Intern Med

    (1975)
  • RM Gipstein et al.

    Calciphylaxis in man

    Arch Intern Med

    (1976)
  • K Lau

    Phosphate excess and progressive renal failure:The precipitation-calcification hypothesis

    Kidney Int

    (1989)
  • EM Widdowson et al.

    Chemical composition of the body

  • BEC Nordin

    Absorption of calcium, phosphorus and magnesium

  • AA Portale et al.

    Oral intake of phosphorus can determine the serum concentrations of 1,25-dihydroxyvitamin D by determining its production rate in humans

    J Clin Invest

    (1986)
  • JH Dominguez et al.

    Dietary phosphate deprivation in women and men: Effects on mineral and acid balances, parathyroid hormone and the metabolism of 25-OH-vitamin D

    J Clin Endocrinol Metab

    (1976)
  • E Reiss et al.

    The role of phosphate in the secretion of parathyroid hormone in man

    J Clin Invest

    (1970)
  • GH LaFlame et al.

    Bone and soft tissue changes with oral phosphate supplements

    J Clin Invest

    (1972)
  • J Jowsey et al.

    Long-term effects of high phosphate intake on parathyroid hormone levels and bone metabolism

    Acta Orthop Scand

    (1974)
  • E Slatopolsky et al.

    On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog

    J Clin Invest

    (1971)
  • E Slatopolsky et al.

    The pathogenesis of secondary hyperparathyroidism in early renal failure

  • Cited by (228)

    • Binding and inhibitory activities: A novel oral therapeutic agent for the treatment of hyperphosphataemia rats

      2022, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Chronic kidney disease (CKD) often presents with elevated serum phosphorus levels and end-stage renal failure because renal insufficiency can reduce urinary phosphate excretion and lead to hyperphosphataemia [3,4]. Clinical observations indicate that hyperphosphataemia is closely associated with various clinical relevant pathologies, such as kidney function deterioration, secondary hyperparathyroidism, renal osteodystrophy, and metastatic calcification [5ā€“8]. Controlling phosphate imbalance in CKD patients is considered a crucial factor in improving the prognosis of patients receiving haemodialysis [9].

    • Trace elements, toxic metals, and metalloids in kidney disease

      2021, Nutritional Management of Renal Disease, Fourth Edition
    • Ī±Klotho and Chronic Kidney Disease

      2016, Vitamins and Hormones
    View all citing articles on Scopus

    Supported in part by US Public Health Service NIDDK Grants No. DK 09976, DK 07126, and RR-00036.

    View full text